Heather J. Sutherland

5.8k total citations · 1 hit paper
132 papers, 3.2k citations indexed

About

Heather J. Sutherland is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Heather J. Sutherland has authored 132 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Hematology, 39 papers in Oncology and 30 papers in Genetics. Recurrent topics in Heather J. Sutherland's work include Multiple Myeloma Research and Treatments (45 papers), Acute Myeloid Leukemia Research (33 papers) and Hematopoietic Stem Cell Transplantation (23 papers). Heather J. Sutherland is often cited by papers focused on Multiple Myeloma Research and Treatments (45 papers), Acute Myeloid Leukemia Research (33 papers) and Hematopoietic Stem Cell Transplantation (23 papers). Heather J. Sutherland collaborates with scholars based in Canada, United States and Spain. Heather J. Sutherland's co-authors include Donna E. Hogge, Allison Blair, Suzanne Vercauteren, John D. Shepherd, Thomas J. Nevill, Donna L. Forrest, Michael J. Barnett, Joan Bladé, J. E. Till and Cynthia L. Toze and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Heather J. Sutherland

126 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

2007 505 citations Heather J. Sutherland et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heather J. Sutherland Canada	30	2.1k	1.3k	1.2k	508	363	132	3.2k
Hervé Maisonneuve France	18	2.4k 1.1×	1.6k 1.2×	1.4k 1.1×	438 0.9×	187 0.5×	90	3.3k
Sikander Ailawadhi United States	28	1.7k 0.8×	1.1k 0.9×	1.4k 1.2×	620 1.2×	287 0.8×	312	3.1k
Reinhard Stauder Austria	36	2.7k 1.3×	1.4k 1.1×	976 0.8×	1.4k 2.7×	536 1.5×	122	4.9k
Dianne Pulte United States	31	1.4k 0.7×	1.0k 0.8×	1.4k 1.2×	569 1.1×	690 1.9×	87	3.5k
Joseph Mıkhael United States	37	3.4k 1.6×	2.9k 2.2×	2.2k 1.8×	828 1.6×	292 0.8×	204	4.8k
Amir T. Fathi United States	34	2.3k 1.1×	1.7k 1.3×	984 0.8×	703 1.4×	769 2.1×	203	3.8k
Joachim Beck Germany	19	1.1k 0.5×	913 0.7×	832 0.7×	277 0.5×	781 2.2×	35	2.5k
Philip C. Amrein United States	27	939 0.4×	743 0.6×	1.0k 0.8×	378 0.7×	452 1.2×	112	2.9k
Alessandro Gozzetti Italy	28	1.7k 0.8×	1.1k 0.8×	1.0k 0.8×	928 1.8×	177 0.5×	147	2.8k
Stig Lenhoff Sweden	26	2.0k 0.9×	877 0.7×	1.0k 0.8×	365 0.7×	295 0.8×	87	2.7k

Countries citing papers authored by Heather J. Sutherland

Since Specialization

Citations

This map shows the geographic impact of Heather J. Sutherland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather J. Sutherland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather J. Sutherland more than expected).

Fields of papers citing papers by Heather J. Sutherland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather J. Sutherland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather J. Sutherland. The network helps show where Heather J. Sutherland may publish in the future.

Co-authorship network of co-authors of Heather J. Sutherland

This figure shows the co-authorship network connecting the top 25 collaborators of Heather J. Sutherland. A scholar is included among the top collaborators of Heather J. Sutherland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather J. Sutherland. Heather J. Sutherland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mourad, Yasser Abou, Donna L. Forrest, Alina S. Gerrie, et al.. (2021). Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population. Clinical Lymphoma Myeloma & Leukemia. 21(7). 476–482. 2 indexed citations

LeBlanc, Richard, et al.. (2021). Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. Clinical Lymphoma Myeloma & Leukemia. 22(1). e41–e56. 17 indexed citations

Song, Kevin, Terry Boyle, Éric Gaudreau, et al.. (2018). Organochlorine Levels in Plasma and Risk of Multiple Myeloma. Journal of Occupational and Environmental Medicine. 60(10). 911–916. 7 indexed citations

Trudel, Suzanne, Nikoletta Lendvai, Rakesh Popat, et al.. (2018). Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. The Lancet Oncology. 19(12). 1641–1653. 192 indexed citations

White, Darrell, Nizar J. Bahlis, Christopher P. Venner, et al.. (2017). A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 130. 1861–1861. 4 indexed citations

Bahlis, Nizar J., Heather J. Sutherland, Darrell White, et al.. (2017). Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM). Blood. 130. 3135–3135.

Gasparetto, Cristina, Suzanne Lentzsch, Gary J. Schiller, et al.. (2017). A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs). Blood. 130. 3100–3100. 2 indexed citations

Tsang, Erica S., Diego Villa, Federica Loscocco, et al.. (2017). Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation. Blood. 130. 3291–3291. 1 indexed citations

Chen, Christine I., Heather J. Sutherland, Rami Kotb, et al.. (2017). Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure. Blood. 130. 3136–3136. 3 indexed citations

10.

Lad, Deepesh, Yasser Abou Mourad, Michael J. Barnett, et al.. (2016). Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies. Biology of Blood and Marrow Transplantation. 22(3). S334–S334. 1 indexed citations

11.

Kliman, David, Michael J. Barnett, Raewyn Broady, et al.. (2016). Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia. Leukemia & lymphoma. 58(4). 909–915. 3 indexed citations

12.

Paulson, Kristjan, Piotr Czaykowski, C Coppin, et al.. (2010). Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study. Bone Marrow Transplantation. 46(6). 852–857. 1 indexed citations

13.

Savoie, Mary Lynn, Kevin Song, Donna L. Forrest, et al.. (2006). Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Annals of Oncology. 17(5). 763–768. 39 indexed citations

14.

Forrest, Donna L., Donna E. Hogge, Thomas J. Nevill, et al.. (2005). High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology. 23(31). 7994–8002. 39 indexed citations

15.

Kuruvilla, John, Donna L. Forrest, Julye C. Lavoie, et al.. (2004). Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation. Bone Marrow Transplantation. 34(11). 969–973. 14 indexed citations

16.

Leong, Kevin G., et al.. (2002). Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia. American Journal of Hematology. 70(1). 22–30. 34 indexed citations

17.

Vercauteren, Suzanne & Heather J. Sutherland. (2001). CD133 (AC133) expression on AML cells and progenitors. Cytotherapy. 3(6). 449–459. 35 indexed citations

18.

Sutherland, Heather J., Donna E. Hogge, P. M. Lansdorp, et al.. (1995). Quantitation, Mobilization, and Clinical Use of Long-Term Culture-Initiating Cells in Blood Cell Autografts. Journal of Hematotherapy. 4(1). 3–10. 12 indexed citations

19.

Barnett, Michael J., Connie J. Eaves, Gordon L. Phillips, et al.. (1993). Allografting in chronic myeloid leukemia with cultured marrow: Update of the vancouver study. Stem Cells. 11(S3). 64–66. 6 indexed citations

20.

Langley, G. R., et al.. (1992). Effect of nonmedical factors on family physicians' decisions about referral for consultation.. PubMed. 147(5). 659–66. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact